Glimepiride monotherapy versus combination of glimepiride and linagliptin therapy in patients with HNF1A-diabetes: a protocol for a randomised, double-blinded, placebo-controlled trial

INTRODUCTION: Hepatocyte nuclear factor 1α (HNF1A)-diabetes is the most common monogenetic subtype of diabetes. Strict glycaemic control is crucial for a good prognosis for patients with HNF1A-diabetes. Sulfonylurea (SU) is used as a first-line therapy in HNF1A-diabetes. However, SU therapy may be p...

Descripción completa

Detalles Bibliográficos
Autores principales: Sidelmann Christensen, Alexander, Storgaard, Heidi, Hædersdal, Sofie, Hansen, Torben, Krag Knop, Filip, Vilsbøll, Tina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2018
Materias:
Diabetes and Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6194456/
https://www.ncbi.nlm.nih.gov/pubmed/30287671
http://dx.doi.org/10.1136/bmjopen-2018-022517

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6194456/
https://www.ncbi.nlm.nih.gov/pubmed/30287671
http://dx.doi.org/10.1136/bmjopen-2018-022517

Ejemplares similares